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Abstract: Small interfering RNA molecules (siRNA) hold great promise to specifically target 
cytoprotective factors to enhance cancer therapy. Like antisense RNA strategies, however, the 
use of siRNA is limited because of in vivo instability. As a first step to overcome delivery issues, 
a series of graft copolymers of polyethylene glycol and polyethylenimine (PEI-g-PEG) were 
synthesized and investigated as nontoxic carriers for delivery of siRNA targeting the signaling 
peptide of secretory clusterin (sCLU), a prosurvival factor that protects cells from ionizing 
radiation (IR) injury, as well as chemotherapeutic agents. Three copolymers with different PEG 
grafting densities were tested for their abilities to bind and form nanocomplexes with siRNA. A 
copolymer composed of 10 PEG grafts (2 kDa each) per PEI polymer (2k10 copolymer) gave the 
highest binding affinity to siRNA by ethidium bromide exclusion assays, and had the smallest 
nanocomplex size (115 ± 13 nm diameter). In human breast cancer MCF-7 cells, 2k10–siRNA-
sCLU nanocomplexes suppressed both basal as well as IR-induced sCLU protein expression, 
which led to an over 3-fold increase in IR-induced lethality over 2k10–siRNA scrambled controls. 
In summary, this study demonstrates the proof-of-principle in using nanoparticle-mediated 
delivery of specific siRNAs to enhance the lethality of IR exposure in vitro, opening the door 
for siRNA-mediated knockdown of specific cytoprotective factors, such as DNA repair, anti-
apoptotic, free radical scavenging, and many other proteins.
Keywords: siRNA delivery, polyethylenimine, nanomedicine, secretory clusterin, cancer 
radiotherapy
Introduction
Small interfering RNA (siRNA) therapy has shown significant therapeutic promise 
against a variety of diseases such as cancer, HIV , and influenza (Brummelkamp et al 
2002b; Novina et al 2002; Ge et al 2004). The ability of siRNA to quickly suppress 
protein expression in an efficient and highly specific manner makes it a prime candidate 
for medical applications. This promise is hampered, however, by in vivo siRNA 
instability, and the fact that agents used for in vitro siRNA delivery tend to be too 
toxic for in vivo applications. Currently, the most common delivery method of siRNA 
for in vitro applications is the use of cationic lipids, such as lipofectamine (Elbashir 
et al 2002). While this system does provide reasonable transfection efficiencies in 
cell culture in vitro, lipofectamine and its related cationic lipids are, in general, 
too toxic for use in vivo. One solution to this problem is to use DNA plasmids that 
direct the synthesis of siRNA. These plasmids have the advantage of inducing more 
persistent gene suppression, as well as being able to be incorporated into viral vectors 
(Brummelkamp et al 2002a; Devroe and Silver 2004). Unfortunately, these viral vectors 
exhibit problems of eliciting immune responses in vivo that hamper their safety for 
clinical applications.
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Cationic polymers have gained prominence in nonviral 
DNA delivery (De Smedt et al 2000),
 although their use in 
siRNA delivery is much more recent. Of these polymers, 
polyethylenimine (PEI) contains primary, secondary, and 
tertiary amines, giving this polymer the unique abilities to 
complex DNA and serve as a low pH (4–5) buffer (Suh et al 
1994). Owing to this buffering capacity or “proton sponge” 
effect, PEI has shown higher transfection efficiency than 
other cationic polymers (Boussif et al 1995). Recently, Ge 
et al (2004) reported the use of PEI–siRNA complexes for 
the treatment of influenza in mice. However, in vivo toxicity 
has been noted for PEI upon intravenous administration. 
To reduce PEI toxicity, polyethylene glycol (PEG) was 
grafted onto PEI, greatly reducing toxicity for the resulting 
gene delivery complexes (Kunath et al 2002). The PEI 
component of the copolymer allows for complexation with 
polynucleotides, and increases endosomal release of the 
nanocomplexes into the cytoplasm. The PEG component not 
only reduces toxicity of the PEI component, but also stabilizes 
the resulting nanocomplex. This modified vector was recently 
used to deliver siRNA targeting the vascular endothelial 
growth factor (VEGF) for treatment of angiogenic tumors 
(Schiffelers et al 2004). To date, polymer-mediated delivery 
of siRNA has not been used in tandem with radiotherapy. 
The clusterin (CLU) gene encodes 2 proteins (1 secreted 
[sCLU]; 1 intracellular and nuclear [nCLU]) through 2 
separate and unique mRNAs. Full-length CLU mRNA 
encodes sCLU protein, a secreted glycoprotein that was 
discovered in 1983 from ram testes fluid (Izawa 1998). This 
protein was subsequently found to be involved in many 
processes, including Alzheimer’s disease (Laping et al 1994), 
tissue regeneration (Little and Mirkes 1995), aging, and 
cancer (Peatfield and Boothman 1991; Welsh 1994; Betuzzi 
2003). The CLU gene can be activated in response to many 
different cell stresses, including ionizing radiation (IR). 
Although nCLU has been shown to induce cell death 
(Yang et al 2000; Klokov et al 2004), sCLU is cytoprotective, 
possibly because of its chaperone-like function (Criswell 
et al 2003; Klokov et al 2004). sCLU protein levels are 
suppressed by p53, resulting in low expression in normal 
human cells, but are expressed at high levels in cancers 
with altered p53 function. Since this protein confers IR 
resistance and is overexpressed in many cancers, including 
breast, prostate, colon, and esophageal (Welsh 1994; Gleave 
et al 2001; July et al 2004), sCLU is a prime target for 
cancer therapy. In fact, phase I clinical trials using antisense 
oligonucleotide therapy against sCLU are currently ongoing 
(Gleave et al 2001). Targeting sCLU protein levels using 
antisense oligonucleotide therapy can increase the lethality 
of treatments using IR, as well as other chemotherapeutic 
agents (Zellweger et al 2003).
In this report, a grafted PEG-g-PEI copolymer was 
used to mediate delivery of siRNA against sCLU (siRNA-
sCLU). The resulting polymer–siRNA-sCLU nanocomplexes 
effectively suppressed sCLU protein expression, which 
led to significantly enhanced IR lethality in MCF-7 
cells. The enhanced efficacy of this treatment strategy 
makes it a promising candidate for target-specific cancer 
radiotherapy. 
Materials and methods 
Materials 
Branched polyethylenimine (PEI, MW 10 kDa) was 
purchased from Polysciences (Warrington, PA, USA). 
Methoxy N-hydroxysuccinimide polyethylene glycol (MeO-
PEG-NHS, 2.0 kDa) was purchased from Nektar Therapeutics 
(San Carlos, CA, USA). Lipofectamine was purchased from 
Invitrogen (Carlsbad, CA, USA). Deionized water was 
treated with diethyl pyrocarbonate (DEPC) and autoclaved 
prior to use. Antibodies to human sCLU (B5) were obtained 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
and α-tubulin antibodies were obtained from Calbiochem 
(La Jolla, CA, USA). The CellTiter 96 Non-Radioactive 
Cell Proliferation Assay Kit was obtained from Promega 
(Madison, WI).
Cell culture 
Human breast cancer MCF-7 cells were cultured in RPMI 
1640 medium containing 5% fetal bovine serum, 2 mM 
glutamine, and 100 IU/mL penicillin–streptomycin in a 95% 
air/5% CO2 humidified atmosphere at 37
oC. MCF-7 cells 
were free from mycoplasma contamination. All cell culture 
reagents were purchased from BioWhittaker (Walkersville, 
ME, USA).
siRNA oligomers 
The double-stranded siRNA 21-mers used for the complex-
ation studies were purchased from Qiagen (Valencia, CA, 
USA). In addition, double-stranded siRNAs directed against 
the signal peptide leader sequence within full-length CLU 
mRNA that encodes sCLU (siRNA-sCLU) or siRNAs 
generated from nontargeted, scrambled sequences (siRNA-
scr) were purchased from Dharmacon (Lafayette, CO, USA). International Journal of Nanomedicine 2006:1(2) 157
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The siRNA-sCLU sequence was: 
5'- GCG UGC AAA GAC UCC AGA AdTdT-3'
3'-dTdTCGC ACG UUU CUG AGG UCU U-5'
The siRNA-scr sequence was:
5'-GCG CGC UUU GUA GGA UUC GdTdT-3'
3'-dTdTCGC GCG AAA CAU CCU AAG C-5'
Syntheses of PEG-g-PEI copolymers 
PEI polymer was first dissolved in deionized H2O at 25 mg/
mL. Different amounts of MeO-PEG-NHS (100, 200, and 
300 mg as solid powders) were added to the above solution 
with magnetic stirring to produce PEG-g-PEI copolymers 
with different PEG grafting densities. The reactions were 
performed at room temperature overnight. After reaction, 
mixtures were purified by membrane dialyses (MW cutoff: 
10 kDa) in distilled water for 2 days. The resulting solutions 
were lyophilized to obtain white solid material (yield 50%–
60%). The molecular weights of the graft copolymers were 
analyzed by gel permeation chromatography on a Zorbax 
GF-250 column (Agilent technologies, Palo Alto, CA) with 
HPLC grade water as eluent (0.3 mL/min). PEG grafting 
densities were characterized by 
1H NMR (Varian Gemini 
NMR spectrometer, Palo Alto, CA, USA) in deuterated 
chloroform by calculating peak ratios of –CH2CH2-O protons 
(3.7–3.8 ppm) from PEG over  –CH2CH2-NH- protons 
(2.3–3.0 ppm) from PEI.
Ethidium bromide (EtBr) exclusion 
assays 
First, aliquots of siRNA (7.8 μg) were solubilized in 
DEPC-treated water at 1.95 μg/mL containing 0.5 μg/mL 
EtBr. EtBr–siRNA fluorescence intensity (λex = 525 nm, 
λem = 590 nm) was measured and set to 100% on an LS-45 
fluorescence spectrometer (Perkin Elmer, Boston, MA). 
Different amounts of PEG-g-PEI copolymer were then added 
in 0.2 N/P increments (each addition had 5 μL volume to 
minimize dilution effects). N/P ratios were calculated as the 
number of nitrogen atoms in the PEI or PEI copolymer over 
that of the phosphate groups in the siRNA. Fluorescence 
intensities were recorded after each addition until final N/P 
ratios of 2.4 were reached. For each addition, the fluorescence 
intensity was measured both immediately after mixing and 
10 minutes later to ensure equilibrium complexation. After 
the experiment, fluorescence intensities were plotted as 
a function of N/P ratio for different graft copolymers to 
compare their binding affinities to siRNA.
Preparation of polymer–siRNA 
nanocomplexes 
An aqueous solution of siRNA (300 μg/mL) was added 
drop-wise to DEPC-treated water containing PEG-g-PEI 
(150–450 μg/mL) while vortexing. Different copolymer 
concentrations were used to provide polymer–siRNA 
nanocomplexes with different N/P ratios. After addition, 
the mixture was vortexed for an additional 20 seconds and 
then allowed to incubate at room temperature for 30 minutes 
before analyses or use. Particle size was determined by 
dynamic light scattering (DLS) on a 90Plus particle size 
analyzer (Brookhaven Instruments, Holtzville, NY, USA).
MTT cytotoxicity assays 
MCF-7 cells were seeded at a density of 2 x 10
4 cells per 
well in 96-well plates 1 day prior to addition of polymers or 
polymer–siRNA nanocomplexes. After addition, cells were 
incubated overnight with either nanocomplexes or equivalent 
concentrations of polymer alone. The CellTiter assay was 
performed according to the manufacturer’s instructions. At 
the end of the incubation, medium was aspirated and replaced 
with 100 μL of diluted MTT dye solution, and cells were 
incubated in a 5% CO2/95% air atmosphere at 37
oC for 4 
hours. Solubilization–Stop Solution was added to each well 
(100 μL) to end reactions, followed by incubation at 37ºC 
for 1 hour. The contents of wells were then mixed by gentle 
pipetting prior to spectrophotometric analyses at a wavelength 
of 550 nm with a reference wavelength of 770 nm. All MTT 
assays were performed in triplicate, and data points were 
calculated as a percentage of viable cells over untreated 
control + standard deviation (SD).
siRNA transfections and western blot 
analysis 
MCF-7 cells were seeded at a density of 3 x 10
5 cells per well 
in a 6-well plate 1 day prior to transfection. Cells were washed 
with RPMI 1640 medium without serum or antibiotics twice 
prior to the addition of siRNA containing nanocomplexes. 
siRNA nanocomplexes or aqueous solutions of polymer 
alone were added to each well, and serum-free RPMI 1640 
medium was added to adjust the total volume to 1.0 mL/well. 
To examine the effects of sCLU knockdown on IR lethality, 
cells were treated with 2 consecutive doses of nanocomplexes 
prior to exposure to ionizing radiation. IR was delivered 
by exposure to a 
60Co sealed source at 580 rad/minute as International Journal of Nanomedicine 2006:1(2) 158
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previously described (Yang et al 2000; Leskov et al 2003). 
After overnight incubation with nanocomplexes, medium was 
removed and replaced with RPMI 1640 medium (2 mL/well) 
containing 5% fetal bovine serum for another 48 hours. At 
harvest, whole-cell extracts were prepared in RIPA buffer 
(0.1% SDS, 0.5% deoxycholate, 1% NP-40, 150 mM NaCl, 
50 mM Tris, pH 8.0). Total protein content was measured 
using standard Bradford assessments, and 50 μg of each 
sample was loaded and proteins separated by SDS-PAGE. 
Western blot analysis was performed as described (Yang 
et al 2000). Quantification of protein expression levels was 
performed using ImageJ software (a freeware distributed 
by the NIH). Western blots shown are representative of 
experiments performed 3 or more times with equivalent 
results. Exposure time for autoradiographs was optimized 
to provide images of adequate quality for analysis. 
Clonogenic survival assays 
MCF-7 cells (3 x 10
5 cells/well) were transfected with 
siRNA-sCLU or siRNA-scr containing (each at 400 pmol) 
nanocomplexes using the 2k10 PEI-g-PEG copolymer. After 
incubation for 60–72 hours, cells were trypsinized, and plated 
onto 60-mm dishes at various cell densities (2000–20000 
cells/dish) in triplicate and irradiated for 12 hours at different 
doses (0–5 Gy). Ten days later, cells were fixed and stained 
using crystal violet in 20% ethanol as described (Criswell 
et al 2005). Colonies containing more than 50 normal-
appearing cells were counted on a Nikon Eclipse TE300 
microscope (Nikon, Melville, NY, USA). Percent survival 
was calculated as the ratio of number of colonies of treated 
cells over untreated control and performed 3 times. Graphed 
are means ± SD versus IR dose in Gy.
Results
Syntheses of PEG-g-PEI copolymers
Three different compositions of grafted copolymers were 
tested for their abilities to complex with siRNA. PEG chains 
with molecular weights of ~2 kDa were grafted onto hyper-
branched PEI (MW 10 kDa) using N-hydroxysuccinimide 
(NHS) chemistry in grafting densities of 5.7, 9.7, and 15.4 
(as estimated by NMR) PEG chains per PEI molecule 
and named 2k5, 2k10, and 2k15, respectively. Upon each 
modification, the amino group on PEI was converted to 
an amide functional group. In all three copolymers, gel 
permeation chromatography demonstrated a monomodal 
peak and 
1H NMR confirmed the grafting density of PEG 
in the copolymer (data not shown).
EtBr exclusion assays
In the formation of nanocomplexes, copolymers bind to 
siRNA molecules primarily through electrostatic interactions 
of the cationic ammonium groups on PEG-g-PEI with the 
negatively charged phosphate groups on the siRNA back-
bone. The polymer–siRNA complexation excludes EtBr from 
siRNA, which leads to a decreased fluorescence intensity. 
Figure 1 plots the normalized fluorescence intensity as a 
function of copolymer addition. The N/P ratio was used 
to reflect the stoichiometry of copolymer over siRNA. All 
the PEG-g-PEI copolymers showed an increase in binding 
affinity over the homopolymer PEI. More specifically, 
unmodified PEI showed a maximal quenching at an N/P 
ratio of 1.6. The 2k5 and 2k15 copolymers both showed 
more effective fluorescence quenching than PEI. The 2k10 
copolymer showed the highest binding to siRNA with 
maximum quenching at an N/P ratio of 1.2. 
Nanocomplex size measurement
Dynamic light scattering was used to determine the hydro-
dynamic diameters of copolymer–siRNA nanocomplexes. An 
N/P ratio of 7 was used for all the copolymers complexing 
with siRNA. PEI formed nanocomplexes with siRNA with 
a diameter of 123 ± 1.8 nm. The 2k5 and 2k15 copolymers 
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Figure 1  PEI-g-PEG copolymers complex with siRNA and exclude EtBr. The 
fluorescence intensity was normalized to the siRNA–EtBr complex prior to 
addition of copolymers. For each copolymer, 2k refers to the molecular weight of 
the grafting PEG chain and 5, 10, or 15 refer to the number of PEG grafts per PEI 
molecule. The inset shows the hydrodynamic diameters of the polymer–siRNA 
nanocomplexes as measured by dynamic light scattering. 
Abbreviations: EtBr, ethidium bromide; PEG, polyethylene glycol; PEI, 
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formed nanocomplexes of 132 ± 5.4 nm and 150 ± 17 nm in 
diameter, respectively. Among all tested copolymers, 2k10 
formed the smallest nanocomplexes with a diameter of 
115 ± 13 nm. Since small particle size has been correlated 
with nanoparticle uptake and transfection efficiency (Zauner 
et al 2001; Prabha et al 2002) and binding affinity is an 
indication of nanoparticle stability, the 2k10 copolymer was 
chosen for subsequent siRNA studies. 
MTT cytotoxicity assessments
The MTT assay (Mosmann 1983) was used to determine the 
short-term cytotoxicity of the 2k10 copolymer and 2k10/
siRNA-sCLU nanocomplexes (Figure 2). Three N/P ratios 
(5, 7, 14) at 3 siRNA doses (200, 400, 800 pmol, siRNA-
scr was used in this study) were examined with siRNA 
alone as a control. Additionally, the same concentrations 
of copolymers alone for each nanocomplex condition were 
examined. Log-phase MCF-7 cells showed no significant 
cytotoxicity after exposure to 200 pmol siRNA alone, 2k10 
alone, or 2k10–siRNA nanocomplexes. At 400 pmol, slightly 
higher cytotoxicity (ie, 75% cell viability, p < 0.05 from 
siRNA alone vs control cells) was observed at an N/P ratio 
of 14 for both 2k10 and 2k10–siRNA nanocomplexes. At 
800 pmol, significant cytotoxicity (> 50% cell lethality) was 
observed at an N/P ratio of 14 for either 2k10 copolymer 
alone or 2k10–siRNA nanocomplexes. High N/P ratios were 
correlated with high transfection efficiencies in PEI-based 
DNA delivery systems (Petersen et al 2002), but high N/P 
ratios also increased cytotoxicity. Subsequent transfection 
studies were performed at an N/P ratio of 7 because of 
cytotoxicity limits. 
2k10–siRNA-sCLU nanocomplexes 
inhibit both basal and IR-inducible 
sCLU expression 
We next investigated the ability of 2k10–siRNA-sCLU 
nanocomplexes to inhibit protein expression of the 
prosurvival factor, sCLU, in log-phase MCF-7 cells before 
(basal levels) and after IR treatment. Changes in basal or IR-
induced levels of sCLU protein expression were monitored 
by expression of the intracellular 60 and ~40 kDa forms 
of sCLU proteins by western blot analyses; we previously 
showed that changes in the intracellular 60 kDa precursor 
form of sCLU can be used to monitor overall sCLU levels 
in the medium of MCF-7 cells (Criswell et al 2003; Klokov 
et al 2004; Criswell et al 2005). Exposure of MCF-7 cells to 
2k10 co-polymer alone that lacked siRNA-sCLU showed no 
inhibition of sCLU protein expression versus untreated cells 
(Figure 3a). Similarly, nanocomplexes made with a siRNA-
scr also showed no inhibition of sCLU protein expression 
in exposed MCF-7 cells. In contrast, exposure of MCF-7 
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Figure 2  Cell viability after co-incubation with siRNA, 2k10, or 2k10–siRNA 
nanocomplexes overnight at different N/P ratios and siRNA doses (n = 6; ± SD) 
Abbreviations: siRNA, small interfering RNA.
Figure 3  Exposure of MCF-7 cells with 2k10–siRNA-sCLU nanocomplexes is 
effective in inhibiting basal and IR-inducible sCLU protein expression. Western blot 
analysis showed basal (a) or IR-inducible (b) sCLU expression was significantly 
knocked down by 2k10–siRNA-sCLU nanocomplexes. An N/P ratio of 7 was used 
for nanocomplex formation before addition to cells. In (b), cells were treated with 
nanocomplexes or vector for 2 consecutive doses prior to exposure to 5 Gy IR. 
Abbreviations: IR, ionizing radiation; sCLU, secretory clusterin; scr, scrambled; 
siRNA, small interfering RNA. 
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cells with nanocomplexes containing siRNA-sCLU showed 
significant inhibition of sCLU expression. Inhibition of 
sCLU protein expression in MCF-7 cells showed a semi-
dose-dependence, with little or no inhibition observed after 
treatment with 200 pmol, but greater inhibition observed 
with 400 pmol. Image analysis estimated a ~60% knockdown 
of sCLU protein expression compared to MCF-7 cells 
exposed to similar nanocomplexes containing siRNA-scr. At 
800 pmol, MCF-7 cells showed similar levels of sCLU protein 
inhibition as observed in MCF-7 cells exposed to 400 pmol 
siRNA-sCLU nanocomplexes. In all cases, siRNA-sCLU 
alone at 200, 400, and 800 pmol showed no inhibition of 
basal sCLU protein expression (data not shown).
Exposure of MCF-7 cells to IR results in significant up-
regulation of CLU gene expression, including > 200-fold 
increases in sCLU protein expression (Boothman et al 1993; 
Yang et al 2000). IR-inducible sCLU protein expression is 
also cytoprotective against IR toxicity in various cancer cells 
(Zellweger et al 2002; Zellweger et al 2003), including in 
MCF-7 cells (Criswell et al 2005). To investigate the efficacy 
of nanocomplexes containing siRNA-sCLU to suppress 
IR-inducible sCLU expression, cells were transfected with 
siRNA-sCLU nanocomplexes and then exposed to IR (5 Gy). 
Neither siRNA-scr nanocomplexes nor 2k10 copolymer alone 
showed protein inhibition versus nonirradiated control cells 
(Figure 3b). Moreover, free siRNA-sCLU oligomers alone did 
not inhibit sCLU protein expression. Importantly, the 2k10–
siRNA-sCLU nanocomplexes showed marked inhibition   
(80% knockdown) of sCLU protein expression (Figure 3b). 
Knockdown of sCLU expression 
enhances IR lethality
Finally, we tested the ability of 2k10–siRNA-sCLU 
nanocomplexes to enhance the radiosensitivity of log-phase 
MCF-7 cells. The 2k10–siRNA-sCLU nanocomplexes 
were tested alongside siRNA-scr nanocomplexes as a 
negative control. As a positive control, siRNA was also 
delivered using a commercially available transfection agent, 
Lipofectamine. Lipofectamine-delivered siRNA-sCLU was 
previously shown to be able to enhance the IR sensitivity 
of MCF-7 cancer cells via suppression of sCLU protein 
expression (Criswell et al 2005). Treatment of MCF-7 cells 
with 2k10–siRNA-sCLU nanocomplexes demonstrated the 
highest sensitivity to IR treatment, with a 38% ± 3% survival 
at 0.5 Gy and a 3% ± 1% survival at 3 Gy. All values were 
normalized to the lethality (95% survival) of unirradiated 
cells. As previously demonstrated, lipofectamine-delivered 
siRNA-sCLU increased the lethality of IR in MCF-7 cells 
(Criswell et al 2005), with 58% ± 4% survival at 0.5 Gy and 
6% ± 1% survival at 3 Gy, compared with 93% ± 5% and 
54% ± 4% survival of nontransfected cells (Criswell et al 
2005). As expected, MCF-7 cells treated with 2k10–siRNA-
scr nanocomplexes showed little to no enhancement of IR 
treatment (Figure 4a). MCF-7 cells treated with siRNA-scr 
nanocomplexes showed 88% ± 12% survival after 0.5 Gy 
and decreasing survival at increasing radiation doses down 
to 12% ± 2% at the 3 Gy dose. 
We also compared the effects of 2k10–siRNA nano-
complexes with 2k10 copolymers alone (Figure 4b). The 
2k10–siRNA-sCLU nanocomplexes showed significantly 
greater IR sensitivity over 2k10 alone (p value < 0.05 at 
all but the highest IR dose), with 2k10 copolymer alone 
having a 50% ± 9% survival at 0.5 Gy falling to a 5% ± 2% 
survival at 3 Gy. MCF-7 cells treated with 2k10 alone showed 
higher IR sensitivity over the MCF-7 cells treated with the 
2k10–siRNA-scr nanocomplexes. 
Discussion
Various PEG-grafted PEI copolymers were synthesized 
and examined for binding to siRNA to form nanometer-
sized complexes. The 2k10 copolymer from this series was 
subsequently shown to be nontoxic and was able to deliver 
siRNA, effectively knocking down basal and IR-inducible 
sCLU protein expression in MCF-7 cells. Consequently, 
these nanocomplexes increased the IR lethality in exposed 
MCF-7 cells. 
Figure 4  Post-IR clonogenic survival assay of MCF-7 cells. (a) Log scale plot of 
cell survival after exposure to 2k10–siRNA-sCLU nanocomplexes compared with 
a positive Lipofectamine control. (b) Cell survival of 2k10 nanocomplexes vs 2k10 
copolymer alone. siRNA-scr nanocomplex was used as a negative control in both 
(a) and (b). Error bars were calculated as the standard deviation from 3 trials.  
*indicates datapoints that are significantly different (p < 0.05) from others in the 
series.
Abbreviations: IR, ionizing radiation; lipof, lipofectamine; sCLU, secretory 
clusterin; scr, scrambled; siRNA, small interfering RNA.International Journal of Nanomedicine 2006:1(2) 161
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Results from this study validate the direct use of EtBr 
binding assays in evaluating siRNA-copolymer affinity.   
Previous reports used DNA oligonucleotides to simulate 
double stranded siRNA to evaluate the interactions of 
copolymers with oligomers (Itaka et al 2004). Since siRNA 
is double stranded, EtBr can intercalate between base pairs   
and sufficient fluorescence was observed to investigate 
copolymer-siRNA interactions. It is worth noting that the 
PEG-grafted PEI copolymer showed a greater fluorescence 
quenching ability than the PEI homopolymer. The enhanced 
quenching ability of the copolymers suggests a stabilization 
effect of PEG in the resulting nanocomplexes, shifting the 
equilibrium towards nanocomplex formation. An optimal 
grafting density of 10 PEG chains per PEI molecule in 
2k10 copolymers was found to give the highest binding 
affinity and nanocomplex stability. This stability also agrees 
with DLS studies, with the 2k10 copolymer forming the 
smallest nanocomplexes. The reduced exclusion of EtBr and 
larger nanocomplex size of the 2k15 copolymer suggests 
that the PEG content in this copolymer is nearing a point 
where PEG chains interfere with siRNA complexation. A 
similar lessening of particle size and greater stabilization 
of nanocomplexes as a result of smaller amounts of PEG 
grafting was previously observed in PEI copolymer 
nanocomplexes with DNA (Petersen et al 2002). Due to the 
favorable siRNA complexation behavior, the 2k10 copolymer 
was subsequently chosen for siRNA studies, as well as its 
ability to knock down sCLU protein levels to enhance IR 
lethality.
Data from MTT assays showed the 2k10 vector had little 
or no toxicity at doses corresponding to 400 pmol or less 
siRNA with N/P ratio as high as 14 (Figure 2). These data 
suggest that PEG lessens the toxicity of the heavily cationic 
PEI portion of the copolymer structure. 
Western blot analysis confirmed that 2k10 was an   
effective carrier for siRNA. The 2k10/siRNA-sCLU 
nanocomplexes inhibited both basal as well as IR-induced 
sCLU expression in MCF-7 cells (Figure 3). sCLU up-
regulation is a very sensitive indicator of cell stress, with 
induction of sCLU expression at levels where most cytotoxic 
agents do not generate significant lethality (Criswell et 
al 2003). Importantly, the slight cytotoxicity of 2k10 
nanocomplexes did not trigger sCLU protein up-regulation 
in MCF-7 cells, as confirmed in all western blot analyses 
(as in representative western blots shown in Figure 3). 
Furthermore, the slight cytotoxicity of 2k10 nanocomplexes 
did not eliminate the copolymer’s ability to effectively inhibit 
sCLU protein expression. Control nanocomplexes containing 
siRNA-scr demonstrate the specificity of siRNA-sCLU, in 
which sCLU protein level was not altered, nor was the IR 
sensitivity of MCF-7 cells exposed to these nanocomplexes. 
siRNA-sCLU delivered by 2k10 nanocomplexes resulted 
in significant enhancement in IR lethality of MCF-7 cells, 
consistent with the specific knockdown of sCLU protein 
expression. The 2k10/siRNA-sCLU nanocomplexes showed 
enhanced IR lethality greater than 3-fold over complexes 
containing siRNA-scr (Figure 4). Importantly, siRNA-sCLU 
nanocomplexes did not affect expression of nCLU protein 
levels (data not shown) as previously shown for this siRNA 
that is directed to the Exon II-encoded, signal leader peptide 
sequence. Thus, the increased IR toxicity is primarily due 
to the specific RNA interference-mediated knockdown of 
sCLU protein levels rather than nonspecific effect of siRNA, 
since this was not observed with the siRNA-scr control. The 
increased toxicity observed in the 2k10 alone over the 2k10–
siRNA-scr nanocomplexes is possibly due to cellular effects   
as a result of uncompleted polymer. Polycations can disrupt   
cell membranes resulting in toxicity (De Smedt et al 2000) and   
the neutralization of that charge by complexation with siRNA   
can lessen or eliminate this toxicity (Brownlie et al 2004). 
It is important to note that the double stranded siRNA 
used in this study is not the only form of RNA silencing 
compound. Short hairpin RNAs, siRNA encoding plasmids, 
and peptide nucleic acids (PNAs) are alternative materials 
that may require different architectures in polymer carriers. 
Despite this, the underlying concepts behind polymer-
mediated siRNA delivery would apply in these cases. 
Meanwhile, polymer carriers and siRNA delivery can show 
marked cell line dependence and subsequent studies will 
explore this possible dependence. 
In summary, PEG-grafted PEI was shown to bind 
to siRNA and form nanometer-sized complexes. These 
nanocomplexes inhibited sCLU expression as well as its IR-
induced up-regulation in MCF-7 cells, resulting in increased 
IR lethality. This study validates the concept of using polymer 
delivered siRNA to specifically down-regulate cytoprotective 
factors as an aid to cancer radiotherapy. Still, questions such 
as nonspecific uptake of these nanocomplexes and their 
targeting efficiency to tumors remain in regard to the in 
vivo translation in animals. Although the small nanoparticle 
size allows for facile i.v. injection, potential barriers may 
still exist for sufficient interstitial penetration in tumors and 
efficient cell uptake. Our laboratories are currently working 
on experiments to address the above issues and aim to 
establish cancer-specific siRNA delivery in vivo to improve 
radiotherapy of human cancers. International Journal of Nanomedicine 2006:1(2) 162
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